2705, boulevard Laurier
R0-709
Québec, Québec
Canada G1V 4G2
Dernières nouvelles
- Font Lavagna, Juan PabloEmployéCHUL+1 418-525-4444, poste 48110juan-pablo.font-lavagna@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-0709
Québec, QC
Canada G1V 4G2 - Gilbert, ÉmilieStagiaireCHUL+1 418-525-4444, poste 48110emilie.gilbert@crchudequebec.ulaval.ca
2705, boulevard Laurier
R0-709
Québec, QC
Canada G1V 4G2 - Gilbert, ÉmilieEmployéCHUL+1 418-525-4444, poste 48110emilie.gilbert@crchudequebec.ulaval.ca
2705, boulevard Laurier
R0-709
Québec, QC
Canada G1V 4G2 - Gilbert, MéganEmployémegan.gilbert@crchudequebec.ulaval.ca
- Obeyi, GerlinsEmployéCHUL+1 418-525-4444, poste 48110gerlins.obeyi@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-0709
Québec, QC
Canada G1V 4G2 - Pageau, KimEmployékim.pageau@crchudequebec.ulaval.ca
- Rabezanahary, HenintsoaEmployéCHUL+1 418-525-4444, poste 48110+1 418-654-2715Henintsoa.Rabezanaha@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2 - Scarrone, MartinaEmployéCHULmartina.scarrone@crchudequebec.ulaval.ca
2705, boulevard Laurier
Québec, QC
Canada G1V 4G2
Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients
Article de revueVaccine, 29 (7), 2011.
Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets
Article de revuePLoS Pathog, 6 (7), 2010.
Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses
Article de revueJ Infect Dis, 201 (5), 2010.
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections
Article de revueClin Infect Dis, 51 (9), 2010.
Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis
Article de revueN Engl J Med, 361 (23), 2009.
A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus
Article de revueJ Infect Dis, 199 (2), 2009.
Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice
Article de revueAntimicrob Agents Chemother, 53 (2), 2009.
Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform
Article de revueVaccine, 26 (27-28), 2008.
Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes
Article de revueAntiviral Res, 77 (2), 2008.
Influenza B viruses isolated in Uruguay during the 2002-2005 seasons: genetic relations and vaccine strain match
Article de revueVirus Res, 123 (1), 2007.
Projets actifs
- Fonds de démarrage, Mariana Baz. La grippe à l'interface entre l'homme et l'animal: émergence et contrôle, du 2020-04-13 au 2023-04-12
- Immunité cellulaire et séroprévalence des anticorps contre SARS-COV-2: Caractérisation de trois populations de travailleurs de l'alimentation, du 2020-11-01 au 2023-03-31
- Understanding the pathogenesis of COVID-19, du 2020-03-01 au 2023-02-28
Projets terminés récemment
- Effects of high polyphenol doses on the replication of COVID-19 in vitro, du 2020-05-01 au 2021-04-30
- Effects of high polyphenol doses on the replication of COVID-19 in vitro, du 2020-06-01 au 2021-11-30
- Innovative therapeutic approaches for the 2019-novel coronavirus, du 2021-03-01 au 2022-02-28
- Prevention of the immunopathology induced by SARS-CoV-2, du 2021-06-01 au 2022-05-31
- Repositionnement du fumarate de diméthyle pour traiter la COVID-19: une molécule à double action au potentiel antiviral et anti-inflammatoire, du 2020-05-11 au 2021-04-30
- Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus, du 2020-05-01 au 2021-03-31